Economic information and modeling reportBudget impact model
Epidemiology and eligible population inputs
13 evidence topics · 11 sources
Budget impact model of ficerafusp alfa: eligible population inputs
No evidence found.
Oral cavity and pharynx cancer incidence in the United States
Laryngeal cancer incidence in the United States
Share of head and neck cancer of squamous cell origin and share presenting with or progressing to recurrent or metastatic disease
Recurrence among older patients with locoregionally advanced disease in SEER-Medicare
“In the resected group (n = 502), 333 patients experienced recurrence and had a 63% increased risk of death vs nonrecurrent patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In those unresected (n = 1,217), 791 patients experienced recurrence and had a 77% increased risk of death” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Share of recurrent or metastatic disease that is HPV-negative
Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States
| Measure, oropharynx, 2012 to 2016 | Value |
|---|---|
| Reported HPV-associated cancers, average annual number | “19,000”View highlighted excerpt for this quote |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)”View highlighted excerpt for this quote |
| Attributable to other HPV types, number (%) | “900 (5)”View highlighted excerpt for this quote |
| HPV-negative, number (%) | “5,500 (29)”View highlighted excerpt for this quote |
HPV status and PD-L1 expression in the first-line pembrolizumab trial population
PD-L1 testing before first-line therapy in United States practice
First-line treatment mix and receipt of later lines in United States practice
“1410 patients (54.7%) were treated with anti-PD1 monotherapy, 577 (22.4%) with combination anti-PD1 plus chemotherapy, and 590 (22.9%) with cetuximab plus chemotherapy in the front-line setting for recurrent or metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Out of 2577 patients, 1128 patients (43.8%) were reported to have received second line treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote